Colfosceril palmitate

Colfosceril palmitate is a type of drug used primarily in the treatment of neonatal respiratory distress syndrome (NRDS). It is a synthetic surfactant, which means it reduces the surface tension inside the lungs, making it easier for the patient to breathe.

History

Colfosceril palmitate was first synthesized in the 1980s as a potential treatment for NRDS, a condition that primarily affects premature infants. It was approved for medical use in the United States in 1990.

Medical uses

The primary use of colfosceril palmitate is in the treatment of NRDS. It is administered directly into the lungs via a process known as endotracheal intubation. This allows the drug to reduce the surface tension in the alveoli, making it easier for the infant to breathe.

Side effects

Like all drugs, colfosceril palmitate can have side effects. These can include bronchospasm, pulmonary hemorrhage, and infection. However, these side effects are relatively rare, and the benefits of the drug often outweigh the potential risks.

Pharmacology

Colfosceril palmitate is a synthetic surfactant, which means it works by reducing the surface tension in the lungs. This makes it easier for the alveoli to stay open, which in turn makes it easier for the patient to breathe.

See also

• Neonatal respiratory distress syndrome
• Surfactant
• Pharmacology

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

‎